Multiplex immunohistochemistry analysis of CTLA4, PD-L1, LAG3 and tumour microenvironment components in relation to MMR status in colorectal carcinoma

被引：0
|
作者：
Naumov, S. [1 ]
Krakhmal, N. [1 ]
Vtorushin, S. [1 ]
机构：
[1] Siberian State Med Univ, Tomsk, Russia
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-24-027
引用
收藏
页码：S157 / S158
页数：2
相关论文
共 50 条
  • [1] Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients
    Kashyap, Seema
    Singh, Mithalesh Kumar
    Kumar, Nikhil
    Jha, Jayanti
    Lomi, Neiwete
    Meel, Rachna
    Bakhshi, Sameer
    Sen, Seema
    Singh, Lata
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2024, 108 (06) : 903 - 912
  • [2] Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020-2024)
    Cheng, Binbin
    Lv, Jinke
    Xiao, Yao
    Song, Changshan
    Chen, Jianjun
    Shao, Chuxiao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 283
  • [3] PD-L1 and LAG3 Expression in Hepatocellular Carcinoma Associated with HCV and Steatohepatitis
    Xing, Dongmei
    Luan, Lan
    Zhu, Qingfeng
    Gani, Faiz
    Pawlik, Timothy
    Taube, Janis M.
    Anders, Robert A.
    LABORATORY INVESTIGATION, 2017, 97 : 426A - 426A
  • [4] PD-L1 and LAG3 Expression in Hepatocellular Carcinoma Associated with HCV and Steatohepatitis
    Xing, Dongmei
    Luan, Lan
    Zhu, Qingfeng
    Gani, Faiz
    Pawlik, Timothy
    Taube, Janis M.
    Anders, Robert A.
    MODERN PATHOLOGY, 2017, 30 : 426A - 426A
  • [5] Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
    Amir Z. Munir
    Alan Gutierrez
    Juan Qin
    Andrew H. Lichtman
    Javid J. Moslehi
    Nature Reviews Cancer, 2024, 24 (8) : 540 - 553
  • [6] Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
    Munir, Amir Z.
    Gutierrez, Alan
    Qin, Juan
    Lichtman, Andrew H.
    Moslehi, Javid J.
    NATURE REVIEWS CANCER, 2024, 24 (08) : 540 - 553
  • [7] PD-1, CTLA4, PD-L1 and PD-L2 DNA methylation in papillary thyroid carcinoma
    de Vos, Luka
    Dietrich, Joern
    Strieth, Sebastian
    Bootz, Friedrich
    Dietrich, Dimo
    Franzen, Alina
    IMMUNOTHERAPY, 2020, 12 (12) : 903 - 920
  • [8] CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1-Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma
    de Vos, Luka
    Cano, Tzaitel Maria Carrillo
    Zarbl, Romina
    Kluemper, Niklas
    Ralser, Damian Johannes
    Franzen, Alina
    Herr, Emmanuelle
    Gabrielpillai, Jennis
    Vogt, Timo Jakob
    Dietrich, Joern
    Strieth, Sebastian
    Landsberg, Jennifer
    Dietrich, Dimo
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (07) : 324 - 334
  • [9] LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers
    Adashek, Jacob J.
    Kato, Shumei
    Pabla, Sarabjot
    Nesline, Mary
    Conroy, Jeffrey M.
    Subbiah, Vivek
    DePietro, Paul
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
    De Giglio, Andrea
    Di Federico, Alessandro
    Nuvola, Giacomo
    Deiana, Chiara
    Gelsomino, Francesco
    CURRENT ONCOLOGY REPORTS, 2021, 23 (11)
12345